Clair Health Bags $11.6 Mn to Advance Wearables for Continuous Women’s Health Monitoring
Advertisement
More than 25,000 people have already joined its waitlist ahead of the planned commercial launch in Nov 2026.
Clair Health, a Virginia-based digital health startup, has secured $11.6 million in funding to accelerate the launch of its noninvasive, hormone-monitoring wearable, designed to continuously track key reproductive hormones and deliver more personalised insights into women's health.
The funding round was led by Khosla Ventures, with participation from a16z speedrun, AI in Health Fund, Brydge Club, Cartan Capital, and angel investor Anne Wojcicki, founder of 23andMe.
According to the startup, more than 25,000 people have already joined its waitlist ahead of the planned commercial launch in Nov 2026.
Clair Health's jewellery-inspired wearable has been designed to continuously monitor estrogen, progesterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and other hormonal biomarkers using a combination of 10 biosensors and more than 130 proprietary biomarkers.
Rather than relying on conventional assumptions about the menstrual cycle, the startup says its technology captures hormonal changes in real time to provide a more individualized understanding of reproductive health.
The startup, founded by Stanford graduates Jenny Duan and Abhinav Agarwal, also integrates artificial intelligence into its platform.
During onboarding, users interact through a voice-based assessment that collects health information and analyzes voice-related biomarkers to estimate the current phase of the user's hormone cycle.
“Wearables are great at monitoring metrics like HRV, sleep, step count, and breathing rate,” said co-founder Jenny Duan. “What they’ve missed is that all of these signals for women are being shaped by their hormones. The data has always been there; we just haven’t had something to read it until now.”
In its beta testing, the company reports identifying nine distinct hormone cycle sub-phases, expanding on the traditional four-phase framework commonly used in menstrual health.
Clair believes this approach could provide more precise information for women managing fertility, hormonal disorders such as polycystic ovary syndrome (PCOS), athletic performance, recovery, and the transition through perimenopause.
The newly raised capital will support continued product development, clinical research, and commercialization efforts as Clair prepares for its market debut later this year.
Stay tuned for more such updates on Digital Health News
